Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-12-032255
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-06-05 14:07:38
Reporting Period:
2012-06-01
Filing Date:
2012-06-05
Accepted Time:
2012-06-05 14:07:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1369868 China Biologic Products Inc. CBPO Biological Products, (No Disgnostic Substances) (2836) 752308816
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
929408 Warburg Pincus & Co. 450 Lexington Avenue
New York NY 10017
Yes No Yes No
1162870 Warburg Pincus Llc 450 Lexington Avenue
New York NY 10017
Yes No Yes No
1220638 P. Joseph Landy C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1239318 R Charles Kaye C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1322709 Warburg Pincus Partners Llc C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1414561 Warburg Pincus X, L.p. C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1414564 Warburg Pincus X Llc C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1414565 Warburg Pincus Private Equity X, L.p. C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
1451560 Warburg Pincus X Partners, L.p. C/o Warburg Pincus Llc
450 Lexington Avenue
New York NY 10017
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-06-01 1,608,363 $12.50 7,876,280 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. The shares of common stock, $0.0001 par value per share (the "Common Stock") reported in Column 4 of this Form 4 were purchased pursuant to a share purchase agreement dated June 1, 2012, entered into by and among Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X" and together with WP X, the "Funds"), IDG-Accel China Growth Fund II L.P. and IDG-Accel China Investors II L.P. (collectively, the "IDG Sellers"). At the closing of the transaction on June 1, 2012, the IDG Sellers sold a total of 1,608,363 Common Stock shares to the Funds for an aggregate purchase price of $20,104,537.50, or $12.50 per share.
  2. As of June 1, 2012, WP X is the holder of an aggregate of 7,632,115 shares of Common Stock of China Biologic Products, Inc. (the "Issuer"). As of June 1, 2012, WPP X is the holder of an aggregate of 244,165 shares of Common Stock of the Issuer. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP") and the sole general partner of each of the Funds, Warburg Pincus X LLC, a Delaware limited liability company ("WP X LLC") and the sole general partner of WP X LP, Warburg Pincus Partners, LLC, a New York limited liability company ("WPP LLC") (continued on footnote 3)
  3. and the sole member of WP X LLC, Warburg Pincus & Co., a New York general partnership ("WP") and the managing member of WPP LLC, Warburg Pincus LLC, a New York limited liability company ("WP LLC") that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-President and Managing Member of WP LLC, may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer held by the Funds. Messrs. Kaye and Landy may be deemed to control the Funds, WP X LP, WP X LLC, WPP LLC, WP and WP LLC. Each of the Funds, WP X LP, WP X LLC, WPP LLC, WP, WP LLC, and Messrs. Charles R. Kaye and Joseph P. Landy is a "Reporting Person" and collectively, the "Warburg Pincus Reporting Persons."
  4. Information with respect to each of the Warburg Pincus Reporting Persons is given solely by such Warburg Pincus Reporting Person, and no Warburg Pincus Reporting Person has responsibility for the accuracy or completeness of information supplied by another Warburg Pincus Reporting Person.
  5. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, each of the Warburg Pincus Reporting Persons, other than the Funds, herein states that this Form 4 shall not be deemed an admission that it or he is the beneficial owner of any of the shares of Common Stock of the Issuer reported in this Form 4. Each of WP X LP, WP X LLC, WPP LLC, WP, WP LLC, and Messrs. Kaye and Landy disclaims beneficial ownership of the Common Stock of the Issuer, except to the extent of its or his pecuniary interest in such shares of Common Stock.